Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.
暂无分享,去创建一个
David A Flockhart | Young-Ran Yoon | Ji-Hong Shon | D. Flockhart | Ji-Young Park | Jae-Gook Shin | Ji-Young Park | Jae-Gook Shin | J. Shon | Sangseop Lee | Y. Yoon | I. Cha | Min-Jung Kim | In-June Cha | Sang-Seop Lee | Se-Wook Oh | Sang-Woo Kim | Min-Jung Kim | Sena Oh | Sang-Woo Kim
[1] R. Levy. Cytochrome P450 Isozymes and Antiepileptic Drug Interactions , 1995, Epilepsia.
[2] E. Tanaka,et al. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system , 1999, Journal of clinical pharmacy and therapeutics.
[3] D. Flockhart,et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[4] D. Greenblatt,et al. Five Distinct Human Cytochromes Mediate Amitriptyline N‐Demethylation In Vitro: Dominance of CYP 2C19 and 3A4 , 1998, Journal of clinical pharmacology.
[5] T. Aoyama,et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.
[6] A. Richens,et al. Effect of Drug Therapy on the Metabolism of Phenytoin , 1975 .
[7] T. Andersson,et al. A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients , 1990, Therapeutic drug monitoring.
[8] I. Niopas,et al. Further insight into the stereoselective interaction between warfarin and cimetidine in man. , 1991, British journal of clinical pharmacology.
[9] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[10] K. Chiba,et al. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. , 1994, British journal of clinical pharmacology.
[11] R. Tukey,et al. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. , 1993, The Journal of pharmacology and experimental therapeutics.
[12] L. Ereshefsky,et al. Antidepressant Drug Interactions and the Cytochrome P450 System , 1995, Clinical pharmacokinetics.
[13] E. Yukawa,et al. The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.
[14] N. Weiss. Definition of screening status in case-control studies of the efficacy of endoscopy. , 1996, Archives of internal medicine.
[15] D. Shen,et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[16] J. Y. Park,et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. , 2001, British journal of clinical pharmacology.
[17] J. Rindone,et al. Phenytoin toxicity associated with ticlopidine administration. , 1996, Archives of internal medicine.
[18] H. Yamazaki,et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[19] H. Gutfreund,et al. Enzyme kinetics , 1975, Nature.
[20] R. Milne,et al. Pharmacokinetic Drug Interactions with Phenytoin (Part I) , 1990 .
[21] Karthik Venkatakrishnan,et al. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine , 2001, European Journal of Clinical Pharmacology.
[22] K. Brøsen,et al. First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype , 1988, Clinical pharmacology and therapeutics.
[23] G. Jones,et al. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. , 1997, Journal of forensic sciences.
[24] R. Gieschke,et al. Interaction studies with moclobemide , 1990, Acta psychiatrica Scandinavica. Supplementum.
[25] M. Barry,et al. Enzyme induction and inhibition. , 1990, Pharmacology & therapeutics.
[26] E. Perucca,et al. Interaction between phenytoin and imipramine. , 1977, British journal of clinical pharmacology.
[27] J S Harmatz,et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. , 2003, British journal of clinical pharmacology.
[28] G. Smith,et al. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.
[29] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[30] S. Wrighton,et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. , 1993, Archives of biochemistry and biophysics.
[31] D. Flockhart,et al. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[32] A. Cicolin,et al. Interactions Between Anticonvulsant and Psychoactive Drugs , 1999, Epilepsia.
[33] P. Baumann,et al. Dextromethorphan and Mephenytoin Phenotyping of Patients Treated with Thioridazine or Amitriptyline , 1992, Therapeutic drug monitoring.
[34] P. Bechtel,et al. Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. , 1989, British journal of clinical pharmacology.
[35] P. Beaune,et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. , 1993, Molecular pharmacology.
[36] Q. Yue,et al. Different effects of inhibitors on the O - and N -demethylation of codeine in human liver microsomes , 1997, European Journal of Clinical Pharmacology.
[37] A. Boobis,et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.